Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 30 of 30 matching drugs for CACNA1S — including drugs targeting any of its 2 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells CACNA1S Direct 2
ethanol, enoxaparin CACNA1S Direct 1
temozolomide, 3'-deoxy-3'-[18f]fluorothymidine, pharmacological study, mibefradil CACNA1S Direct 1
amlodipine CACNA1S Direct yes 0
amlodipine besylate CACNA1S Direct yes 0
amlodipine maleate CACNA1S Direct yes 0
bepridil CACNA1S Direct yes 0
bepridil hydrochloride CACNA1S Direct yes 0
cinnarizine CACNA1S Direct yes 0
clevidipine CACNA1S Direct yes 0
diltiazem CACNA1S Direct yes 0
diltiazem hydrochloride CACNA1S Direct yes 0
diltiazem malate CACNA1S Direct yes 0
dronedarone CACNA1S Direct yes 0
dronedarone hydrochloride CACNA1S Direct yes 0
gabapentin CACNA1S Direct yes 0
gabapentin enacarbil CACNA1S Direct yes 0
lercanidipine CACNA1S Direct yes 0
lercanidipine hydrochloride CACNA1S Direct yes 0
levamlodipine CACNA1S Direct yes 0
nicardipine CACNA1S Direct yes 0
nicardipine hydrochloride CACNA1S Direct yes 0
nitrendipine CACNA1S Direct yes 0
pregabalin CACNA1S Direct yes 0
suloctidil CACNA1S Direct yes 0
terodiline CACNA1S Direct yes 0
terodiline hydrochloride CACNA1S Direct yes 0
verapamil CACNA1S Direct yes 0
verapamil hydrochloride CACNA1S Direct yes 0
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin MYC SSL via MYC 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.